GSK (GSK) Q3 2026 Earnings Call Transcript

GSK reported Q3 2026 sales of £8.9 billion, up 5% at constant exchange rates, while specialty medicines rose 15%; core operating profit also grew 5%, and core EPS increased 1%. Management reconfirmed full-year guidance, with sales and core operating profit expected in the upper half of their ranges, operating margin above 31%, and royalties upgraded to about £900 million. R&D investment rose 22%, with 18 of 22 targeted Phase III trial starts underway, while £0.3 billion of restructuring charges were recorded in the quarter and 2026 charges may reach £1 billion. Offsetting risks include projected FX headwinds of 1% on sales and 3% on operating profit, higher financing costs after the Nuvalent acquisition, and a negotiated Trelegy price of $175 for a 30-day supply, 73% below its 2024 list price from 2027.

Analysis

The investment debate is shifting from whether GSK can grow specialty sales to whether that growth converts into per-share earnings after R&D, financing and currency. Stable operating profit alongside weak EPS conversion makes the near-term quality of growth less compelling than the launch narrative; restructuring savings may fund the pipeline, but should not be capitalized as durable margin expansion until savings exceed reinvestment. The key second-order risk is 2027: Trelegy’s negotiated pricing, the Biktarvy royalty step-down and higher financing costs can offset launch growth even if operating execution remains sound.

Specialty momentum could improve mix and reduce reliance on mature primary-care products, but phase III starts are inputs, not probability-adjusted value. For Exdensur, reimbursement access may unlock initial prescribing, while repeat dosing and persistence—not early starts—will determine whether it becomes a meaningful revenue stream. Hibsago’s finite-course proposition is commercially attractive, but monitoring burden and reimbursement/access could constrain uptake. Shingrix inventory makes reported demand noisier; avoid extrapolating a quarter’s shipments into end-demand.

Contrarian read: the market may over-credit pipeline acceleration and underweight earnings conversion and 2027 offsets. Conversely, treating the Trelegy price reduction as a direct 73% net-revenue cut would also overstate the hit; verify realized net pricing and volume. Near term, execution and currency dominate; over 6–18 months, launch persistence, clinical readouts and debt costs determine whether the specialty pivot earns a higher multiple.

Key Decisions for Investors

• Prefer a modest GSK long relative to a broad pharma basket on pullbacks, not an unhedged results-day chase. The thesis is specialty mix and launch execution; size conservatively because financing and 2027 revenue offsets can dilute EPS gains. Reassess if operating-profit growth no longer keeps pace with sales or full-year margin guidance is cut.
• Treat Exdensur and Hibsago as catalyst watches, not yet standalone growth assumptions. Verify quarterly paid starts, repeat dosing/persistence, access coverage and reimbursement; lack of follow-through after initial access gains would falsify the launch-ramp thesis.
• Track GSK’s 2027 earnings bridge: realized Trelegy net price/volume, Biktarvy royalty expiry, net interest expense and restructuring cash costs. Rising interest expense toward the upper end of management’s outlook without offsetting operating leverage argues for reducing exposure.
• Do not trade Shingrix on shipment growth alone. Use pharmacy inventory normalization and China reorder evidence to distinguish sell-in from demand; inventory unwind or delayed replenishment would weaken the vaccine-growth case.